Comparison · NCT00788892-sae
Arm A: CPX-351 vs Arm B: Cytarabine + Daunorubicin: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A: CPX-351 vs Arm B: Cytarabine + Daunorubicin: serious adverse events. Trial comparisons, record NCT00788892-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00788892-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.553 | 0.447 | 0.654 | wilson | |
| Risk in group 2 | 0.39 | 0.257 | 0.543 | wilson | |
| Risk difference, group 1 minus group 2 | 0.163 | -0.0228 | 0.33 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.42 | 0.924 | 2.17 | log | |
| Odds ratio, group 1 over group 2 | 1.93 | 0.904 | 4.13 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Arm A: CPX-351 than on Arm B: Cytarabine + Daunorubicin | 6.15 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A: CPX-351 | First induction: CPX-351 at 100u/m2 administered on days 1, 3 and 5 Second induction: CPX-351 at 100u/m2 administered on days 1 and 3 Consolidation: CPX-351 at 100u/m2 administered on days 1 and 3 | 47 | 85 | EG000 |
| Group 2 | Arm B: Cytarabine + Daunorubicin | First induction: Cytarabine at a dose of 100mg/m2/day on days 1-7, Daunorubicin at dose of 45 or 60mg/m2 on days 1-3 Second induction: Cytarabine at a dose of 100mg/m2/day on days 1-5, Daunorubicin at a dose of 45 or 60 mg/m2/day on days 1 and 2 Consolidation: Investigator's Choice | 16 | 41 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Assessed during treatment period and recorded and reported any new serious adverse events (up to 30 days after completion of Treatment Period)
Source ClinicalTrials.gov
Trial
- Title
- Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
- NCT number
- NCT00788892
- Phases
- PHASE2
- Conditions
- Acute Myeloid Leukemia
- Interventions
- CPX-351, Cytarabine, Daunorubicin
- Lead sponsor
- Jazz Pharmaceuticals
- Results first posted
- 2018-01-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00788892?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00788892-sae